iCell Gene Therapeutics

Shenzhen, Guangdong

OncologyantibodyFiled/Approved

Compare Sign in to watch

What changed

Phase III trial registered: Efficacy and Safety of Immunoglobulin Plus Firsekibart in Patients With Kawasaki Disease

1w agoTrial registeredJul 7, 2026Source filing (opens the source filing in a new tab)

Momentum

92no change

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Filed/Approved

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

102 pre-ticker oncology companies at Filed/Approved

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

Trial
PHASE2/PHASE3 registered
Aug 1, 2026
Kawasaki Disease · NOT_YET_RECRUITING · sponsor: Children's Hospital of Fudan University · Efficacy and Safety of Immunoglobulin Plus Firsekibart in Patients With Kawasaki Disease
ClinicalTrials.gov · NCT07686770 (opens the source filing in a new tab)
Trial
EARLY_PHASE1 registered
Oct 15, 2025
Malignant Meningioma · NOT_YET_RECRUITING · sponsor: Nanjing Medical University · γδ T-PD-1 Ab Cells in the Treatment of Malignant Meningioma
ClinicalTrials.gov · NCT07172178 (opens the source filing in a new tab)
Trial
PHASE4 registered
Jun 1, 2025
Kawasaki Disease, Coronary Artery Aneurysm · RECRUITING · sponsor: Children's Hospital of Fudan University · Rivaroxaban for Children Aged Over 2 Years With Giant Coronary Artery Aneurysms After Kawasaki Disease
ClinicalTrials.gov · NCT05643651 (opens the source filing in a new tab)
Trial
NA registered
Apr 1, 2025
Stroke · NOT_YET_RECRUITING · sponsor: Hong Kong Metropolitan University · Effects of IMT on Respiratory, Diaphragmatic and Balance Functions, Exercise Capacity and QOL in People After Stroke
ClinicalTrials.gov · NCT06447272 (opens the source filing in a new tab)
Trial
PHASE3 registered
Sep 10, 2024
Helicobacter Pylori Eradication Rate · RECRUITING · sponsor: Eighth Affiliated Hospital, Sun Yat-sen University · Optimization of Keverprazan-amoxicillin Dual Therapy for Eradicating Helicobacter Pylori Infection
ClinicalTrials.gov · NCT06734260 (opens the source filing in a new tab)
Trial
Study registered
Jan 1, 2023
Kawasaki Disease, Coronary Artery Aneurysm, Rivaroxaban, Anticoagulant Drugs, Pharmacokinetics and Pharmacodynamics · RECRUITING · sponsor: Children's Hospital of Fudan University · Pharmacometrics Analysis of Rivaroxaban in Chinese Children Aged Over 2 Years
ClinicalTrials.gov · NCT06993636 (opens the source filing in a new tab)
Trial
PHASE1 registered
Jul 1, 2019
Multiple Myeloma in Relapse, Refractory Multiple Myeloma, Plasmacytoid; Lymphoma · RECRUITING · sponsor: iCell Gene Therapeutics · BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma
ClinicalTrials.gov · NCT04162353 (opens the source filing in a new tab)

How this crosswalk was built

Confidence 74%Edges merged automatically, not yet reviewed by a human

Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator

Links score at or above 0.86 to merge automatically. Anything below that and above the review line goes to a human queue. Resolution is a judgment, and it can be wrong. How resolution works.

Event stream

Every scored event, newest first. This is what momentum is computed from.

Phase III trial registered: Efficacy and Safety of Immunoglobulin Plus Firsekibart in Patients With Kawasaki Disease
1w agoTrial registeredSource (opens the source filing in a new tab)
Filed/Approved trial registered: Rivaroxaban for Children Aged Over 2 Years With Giant Coronary Artery Aneurysms After Kawasaki Disease
2w agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: Rivaroxaban for Children Aged Over 2 Years With Giant Coronary Artery Aneurysms After Kawasaki Disease
2w agoTrial recruitingSource (opens the source filing in a new tab)
Phase III trial registered: Optimization of Keverprazan-amoxicillin Dual Therapy for Eradicating Helicobacter Pylori Infection
7mo agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: Optimization of Keverprazan-amoxicillin Dual Therapy for Eradicating Helicobacter Pylori Infection
7mo agoTrial recruitingSource (opens the source filing in a new tab)
Phase I trial registered: BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma
10mo agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma
10mo agoTrial recruitingSource (opens the source filing in a new tab)
Phase I trial registered: γδ T-PD-1 Ab Cells in the Treatment of Malignant Meningioma
10mo agoTrial registeredSource (opens the source filing in a new tab)
Study registered, no phase assigned: Pharmacometrics Analysis of Rivaroxaban in Chinese Children Aged Over 2 Years
May 2025Trial registeredSource (opens the source filing in a new tab)
Trial now recruiting: Pharmacometrics Analysis of Rivaroxaban in Chinese Children Aged Over 2 Years
May 2025Trial recruitingSource (opens the source filing in a new tab)
Study registered, no phase assigned: Effects of IMT on Respiratory, Diaphragmatic and Balance Functions, Exercise Capacity and QOL in People After Stroke
Mar 2025Trial registeredSource (opens the source filing in a new tab)

Last disclosed raise

No Form D is on file, so there is no raise to model a runway from. That is why the runway reads “—” rather than a number. It does not mean the company has no money: grants, revenue and notes below the Form D threshold are all invisible here.

Something wrong on this page? The crosswalk is a judgment and we would rather hear it. Report a bad link.

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources

Peer position

Grant to raise

PHASE2/PHASE3 registered

EARLY_PHASE1 registered

PHASE4 registered

NA registered

PHASE3 registered

Study registered

PHASE1 registered